Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01425008 · ClinicalTrials.gov registry record · Phase 1
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 149
- Enrollment target
NCT01425008: Completed Phase 1 study, sponsored by Millennium Pharmaceuticals.
NCT01425008 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 149 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (148% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01425008, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 149 participants
- Enrollment target
Study Summary
This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion. The Dose Escalation phase will include participants with solid tumors (including melanoma) who have failed or are not candidates for standard therapies or for whom no approved therapy is available. The Dose Expansion phase will include participants with metastatic melanoma.
Interventions
- DRUG MLN2480
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2011-09-15 |
| Est. Completion | 2018-10-16 |
| Phase | Phase 1 |
What the finished NCT01425008 record still lists
NCT01425008 is an interventional study that assigns participants to a tested intervention. The registered 149 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (148% higher).
The record links to 0 conditions, and to 1 intervention - of which MLN2480 is the first listed.
NCT01425008 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01425008 about?
NCT01425008 is a clinical study titled "Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma". This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion. The Dose Escalation phase will include participants with solid tumors (including melanoma) who have failed or are not candidates for standard...
What is the current status of trial NCT01425008?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 149 participants. The study started on 2011-09-15. Estimated completion is 2018-10-16.
What interventions are being tested in trial NCT01425008?
The interventions under investigation include: MLN2480 (DRUG).
Who is sponsoring clinical trial NCT01425008?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01425008's enrollment target sits among peer trials
149 381st of 2000 higher than 1,619 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04188535 · 149 participants · NA
Serial MRI Scans During Radiation Therapy
- NCT05828511 · 149 participants · Phase 1
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI